Lord, Abbett & Co
IMGN

Lord, Abbett & Co’s Immunogen Inc IMGN Stock Holding History

Lord, Abbett & Co’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-759,450
Closed -$12.1M – 604
2023
Q3 		$12.1M Sell
759,450
-159,545
-17% -$2.65M 0.04% 374
2023
Q2 		$17.3M Buy
+918,995
New +$10.9M 0.06% 365

Other funds holding IMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Lord, Abbett & Co's IMGN Position: Q4 2023 in Review

Lord, Abbett & Co sold out of Immunogen Inc (IMGN) in Q4 2023, closing a stake of 759,450 shares — an estimated $12.1M sold.

Lord, Abbett & Co first reported a position in IMGN in Q2 2023 and held it in 2 quarters. The position peaked at $17.3M in Q2 2023. 327 funds tracked by Wall St. Rank hold IMGN as of Q4 2023.

  • Lord, Abbett & Co reported no remaining Immunogen Inc position as of Q4 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 759,450 Immunogen Inc shares in Q4 2023, an estimated $12.1M.
  • Lord, Abbett & Co first reported a position in Immunogen Inc in Q2 2023 and held it in 2 quarters.
  • Lord, Abbett & Co's Immunogen Inc position peaked at $17.3M in Q2 2023.
  • 327 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2023.

Based on Lord, Abbett & Co's 13F filing for Q4 2023, filed 12 Feb 2024.